Tag: RenalGuard

New Study Demonstrates Feasibility of Using RenalGuard-Guided Diuretic Therapy for Acute Heart Failure Patients

MILFORD, Mass. & VIENNA–(BUSINESS WIRE)–RenalGuard Solutions™, Inc., a medical device company focused on innovative fluid management technologies for the cardiac and vascular markets, today announced new clinical study results demonstrating the feasibility of using RenalGuard®-Guided Diuretic Therapy to optimize fluid management in Acute Decompensated Heart Failure (ADHF) patients while alleviating […]

RenalGuard Solutions Announces Late Breaking Clinical Trial Data Accepted for Presentation at Heart Failure 2018

MILFORD, Mass.–(BUSINESS WIRE)–RenalGuard Solutions™, Inc., a medical device company focused on innovative fluid management technologies for the cardiac and vascular markets, today announced that new data from a clinical trial studying RenalGuard®-Guided Diuretic Therapy will be presented as a late breaking abstract at Heart Failure 2018, the annual meeting of […]

RenalGuard Solutions Announces Appointment of Dr. Howard R. Levin as Chief Medical Officer

MILFORD, Mass.–(BUSINESS WIRE)–RenalGuard Solutions™, Inc., a medical device company focused on innovative technologies for the cardiac and vascular markets, today announced that Howard R. Levin, M.D., has been named the company’s chief medical officer. A veteran in the field of biomedical engineering and cardiology and one of the original developers […]

RenalGuard System Demonstrates Promising Results from First-in-Man Studies to Evaluate Technology for Heart Failure Patients

MILFORD, Mass.–(BUSINESS WIRE)– RenalGuard Solutions, Inc., a medical device company focused on innovative technologies for the cardiac and vascular markets, today reported positive results from a first-in-man feasibility study focusing on a novel use of the RenalGuard System® to manage fluids during diuretic therapy in congestive heart failure patients suffering from fluid […]

Meta-Analysis Shows RenalGuard(R) Offers Dramatic Benefit for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Cardiovascular Interventions

MILFORD, MA–(Marketwired – September 13, 2017) – A new meta-analysis suggests that the use of the RenalGuard System® reduces the rate of contrast-induced acute kidney injury (CI-AKI) compared to standard intravascular volume expansion in moderate-to-high-risk patients with chronic kidney disease who are undergoing cardiac interventional procedures. The study, published in the Journal […]

RenalGuard Names Former St. Jude Medical (STJ)-Abiomed (ABMD) Exec as New CEO

MILFORD, MA–(Marketwired – July 10, 2017) – RenalGuard Solutions, Inc. today announced the appointment of Jim Dillon, former St. Jude Medical and Abiomed commercial executive, as Chief Executive Officer. “Jim joins RenalGuard with a proven record of executive leadership related to innovative medical devices that serve the needs of the interventional […]